Novartis’ Pharmaceuticals Have the Best Stock Rates for year 2012

Novartis is an International company in Basel, Switzerland. It has been ranked as number two among other companies in U.S. industry, in 2010. It is a pharmaceutical company that manufactures drugs as Voltaren and Diovan. In 1996, Sandoz merged with another pharmaceutical company to form Novartis. Its services also provide agrochemical products to its customers. Later, in year 2003, Novartis introduced a new generic product and named it Sandoz Novartis. It is a member of International Federation of Pharmaceutical Association and European Pharmaceutical Association.

Novartis stock records that in year 2010, the company’s stock rate was 46.806 billion U.S. Dollars that is the second highest stock rate. According to Novartis Stock Graphs of year 2012, the highest ranked drug of company is Gilenya, with stock rate 1,195 that is 142% of normal sale. Second among top twenty products of annual sale is Afinitor/Sertican/Zortress, with its stock rate $797 million at 80% sale.

Novartis Stock Prices for its pharmaceutical products have distinguished its stock rate in drug industry. The Company’s recorded highest stock rate for year 2012 is 2,398 million U.S. dollars for a drug named by the company as Lucentis that is a drug for age-related macular degeneration. Other top rated drugs of Novartis Company includes Galvus that is a drug for diabetes, Exforge that is a medicine for hypertension, Myforticthat prevents from transplant rejection and Xoliar that is for asthma patients. Apart from these drugs, there are many other pharmaceutics that raised the stock rates of the company to its best.